CFI-400945 is primarily utilized in cancer research due to its role as a potent and selective inhibitor of Polo-like kinase 4 (PLK4). PLK4 is a key regulator of centriole duplication, a process critical for cell division. By inhibiting PLK4, CFI-400945 disrupts centriole formation, leading to mitotic defects and ultimately inducing cell death in cancer cells. This mechanism makes it a promising candidate for targeting cancers with elevated PLK4 activity or those dependent on proper centriole function. It is particularly studied in the context of solid tumors, including breast, prostate, and lung cancers. Additionally, CFI-400945 is being explored in combination therapies to enhance the efficacy of existing cancer treatments. Its potential to selectively target cancer cells while sparing normal cells underscores its significance in developing novel anticancer strategies. Ongoing clinical trials aim to evaluate its safety, tolerability, and therapeutic potential in human patients.